2024 Spanish Society of Internal Medicine (SEMI) recommendations for the management of cancer-associated venous thromboembolism
- PMID: 39490527
- DOI: 10.1016/j.rceng.2024.10.007
2024 Spanish Society of Internal Medicine (SEMI) recommendations for the management of cancer-associated venous thromboembolism
Abstract
Vennous thromboembolism (VTE) is a common complication associated to greater mortality in patients with cancer. Its etiology is multifactorial and depends on the characteristics and co-morbidities of the patient, the tumor type and extension, and the oncological treatment. The management of VTE is more complex in patients with cancer due to an increased risk of recurrence and major bleeding complications during anticoagulation compared to the general non-oncological population. The above differences have led to the development of specific clinical trials to assess the efficacy and safety of anticoagulant therapy in patients with cancer. The present clinical guidelines are intended to provide general recommendations on the management of cancer-associated VTE according to updated according to the most recent scientific evidence.
Keywords: Cancer-associated thrombosis; Consensus recommendations for clinical practice; Paraneoplastic thrombosis; Recomendaciones de consenso para la práctica clínica; Trombosis asociada al cáncer; Trombosis paraneoplásica.
Copyright © 2024 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.
Conflict of interest statement
Conflicts of interest Aurora Villalobos has received speaker’s fees from the following pharmaceutical companies: Leo Pharma, Pfizer, ROVI, Sanofi, and Techdow and has participated in an advisory role for Pfizer. Pablo Demelo-Rodríguez has received speaker’s fees from the following pharmaceutical companies: Bayer, Bristol-Myers, Daiichi Sankyo, Leo Pharma, Menarini, Pfizer, ROVI, Sanofi, and Techdow and has participated in an advisory role for Leo Pharma, Pfizer, and Techdow. Carme Font has received speaker’s fees from the following pharmaceutical companies: Daiichi Sankyo, Leo Pharma, Pfizer, ROVI, Sanofi, and Techdow and has participated in an advisory role for Leo Pharma and Pfizer.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
